CLINICAL PROCEEDINGS
CNSA Clinical Proceedings are a series of informational resources intended to raise awareness and address unmet needs in neurology. Authored by expert panelists, these white papers, webinars and surveys serve to advance the Society’s role in providing thought leadership highlighting the latest trends and topics in the field of neurology.
Rett Syndrome
This paper conveys the clinical perspectives and patient journey of those living with Rett Syndrome, a rare disorder affecting primarily women. The white paper also explores the unmet needs surrounding timely diagnosis and the benefits of novel treatments.
The expert panel for this paper is:
- Jeffrey Neul, MD, PhD – Chair
- Dick Gunderman, MD
- Laura Lehman, MD, MPH
- Alan K. Percy, MD
This Clinical Proceedings white paper was supported in part with a grant from Acadia Pharmaceuticals.
Pseudobulbar Affect (PBA)
This paper conveys the perspectives of neurologists as to the challenges involved in clinically managing patients with PBA. PBA is a complicated condition that is characterized by episodes of sudden uncontrollable and inappropriate laughing or crying. The current PBA diagnosis and clinical management landscapes have pressing needs.
CNSA’s expert panel considered, from a clinical perspective, the patient journey of those experiencing PBA. Clinicians relied on their real-world experience as well as existing research and the perspectives of other stakeholders to develop the publication.
The expert panel for this paper is:
- Philip B. Gorelick, MD, MPH – Chair
- Yvonne Curran, MD
- Muhammad “Umar” Farooq, MD, FAHA, FACP, RPNI
- Howard S. Kirshner, MD
- Richard Zweifler, MD
This Clinical Proceedings white paper was supported in part with a grant from Avanir Pharmaceuticals, Inc.
Accelerated Approval Program
With a number of drugs for a range of neurological conditions being considered via the FDA’s Accelerated Approval process, CNSA prepared a three-phase initiative that began with an assessment of neurologists’ perceptions and gaps in understanding about the program and ended with the development of a white paper and webinar.
The Accelerated Approval initiative was supported in part with contributions from Biogen, Lilly and PhRMA.
Alzheimer's Disease Psychosis
This paper conveys the clinical perspectives as to the challenges in treating patients with Alzheimer’s disease psychosis when no approved therapy is available. The white paper also explores the impact of the unmet needs of Alzheimer’s disease psychosis on patients, clinicians, caregivers and the health care system, as well as societal ramifications.
The expert panel for this paper is:
- Howard S. Kirshner, MD – Chair
- Jeffrey L. Cummings, MD, ScD
- Patrick Griffith, MD
- Christina Mayville, MD
- William Petrie, MD
This Clinical Proceedings white paper was supported in part with a grant from Acadia Pharmaceuticals.
